Trial · NCT01234922
Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors
NCT01234922, Phase 2, Terminated, Wake Forest University Health Sciences; results first posted 2014-12-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors. Trials, record NCT01234922. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01234922
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors
- NCT number
- NCT01234922
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- Wake Forest University Health Sciences
- Conditions
- Hypertension, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- lisinopril, losartan potassium, laboratory biomarker analysis, benazepril hydrochloride, ramipril
- First posted
- 2010-11-04
- Last updated
- 2018-08-28
- Results first posted
- 2014-12-15
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter | 7 days post-baseline | |
| Secondary | Change in Ang II, VEGF, PlGF, and ACE Levels | 1 week |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter | 7 days post-baseline | Picogram/milliliter | MEAN | |
| SECONDARY | Change in Ang II, VEGF, PlGF, and ACE Levels | 1 week | Data were not analyzed due to insufficient accrual to the study and lack of statistical power. |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter | Arm I | 13.25 | Standard Deviation 0 | Picogram/milliliter | |
| Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter | Arm II | 33.67 | Standard Deviation 0 | Picogram/milliliter | |
| Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter | Arm III | 6.685 | Standard Deviation 10.815 | Picogram/milliliter | |
| Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter | Arm IV | 5.045 | Standard Deviation 5.275 | Picogram/milliliter |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm I | 1 | |
| Overall Study | STARTED | Arm II | 1 | |
| Overall Study | STARTED | Arm III | 2 | |
| Overall Study | STARTED | Arm IV | 2 | |
| Overall Study | COMPLETED | Arm I | 1 | |
| Overall Study | COMPLETED | Arm II | 1 | |
| Overall Study | COMPLETED | Arm III | 2 | |
| Overall Study | COMPLETED | Arm IV | 2 | |
| Overall Study | NOT COMPLETED | Arm I | 0 | |
| Overall Study | NOT COMPLETED | Arm II | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events40
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hemoglobin | Investigations | Arm I | 1 | 1 | 1 |
| other | Hemoglobin | Investigations | Arm II | 0 | 1 | 0 |
| other | Hemoglobin | Investigations | Arm III | 0 | 2 | 0 |
| other | Hemoglobin | Investigations | Arm IV | 0 | 2 | 0 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Arm I | 1 | 1 | 1 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Arm II | 0 | 1 | 0 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Arm III | 0 | 2 | 0 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Arm IV | 0 | 2 | 0 |
| other | hyperglycemia | Investigations | Arm I | 1 | 1 | 1 |
| other | hyperglycemia | Investigations | Arm II | 1 | 1 | 1 |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm I | ||
| Total, all-cause mortality | Arm II | ||
| Total, all-cause mortality | Arm III | ||
| Total, all-cause mortality | Arm IV | ||
| Total, other adverse events | Arm I | 1 | 1 |
| Total, other adverse events | Arm II | 1 | 1 |
| Total, other adverse events | Arm III | 1 | 2 |
| Total, other adverse events | Arm IV | 2 | 2 |
| Total, serious adverse events | Arm I | 0 | 1 |
| Total, serious adverse events | Arm II | 0 | 1 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01234922
GET https://conductscience.org/api/trials/v1/NCT01234922/events?page=2